课题基金 / 基金详情

Passive immunotherapy using plant-derived broadly HIV-1 neutralizing MAbs to prev

Passive immunotherapy using plant-derived broadly HIV-1 neutralizing MAbs to prev
使用植物来源的广泛 HIV-1 中和单克隆抗体进行被动免疫疗法来预防
批准号:
7685238
负责人:
Yvonne J Rosenberg
金额:
$25.65万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-03-15 至 2010-02-28

项目摘要

项目成果

Yvonne J Rosenberg的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):虽然许多艾滋病毒疫苗方案已经引起了强大的病毒特异性T细胞反应,但它们无法预防感染。到目前为止,被动免疫疗法与少量广泛中和的单抗(MAb)相结合,对猴子的SIV攻击提供了最好的保护。然而,在全球范围内,所需的大量多剂量将对现有昂贵的微生物发酵或基于细胞的生产系统产生过高的需求。植物表达将提供一种廉价、安全、可快速扩展的替代方案。基因工程植物已经成功地用于生产许多复杂的蛋白质,包括免疫球蛋白、SIgA、疫苗抗原、酶和生长因子。这项第一阶段研究的目的是利用农杆菌渗透/注射在植物中生产高表达的单抗,并评估它们在体外广泛中和HIV-1分离株的能力。在烟草中将产生几种具有良好特性的包膜特异性单抗:2G12、2F5、4E10、IgG1b12以及针对CD4诱导的gp120表位的单抗。为了检测N-糖基化对这些单抗中和作用的影响,我们将产生内质网保留的“高甘露糖”形式和分泌的“复合糖链”形式,并与CHO来源的蛋白进行比较。随着这些研究的进行,产生稳定转基因烟草的过程将会变得更慢。这将通过共表达DsRed荧光标记来识别抗体表达系并追踪转基因后代。在目前的环境下,使用非食用、非饲料作物来生产重要的治疗性蛋白质具有许多优势。在第二阶段,那些既高水平表达又具有很强中和活性的单抗将由转基因植物或大规模瞬时表达烟草产生,并测试它们预防SIV毒株攻击猴子的能力。与公共卫生相关性:与艾滋病毒疫苗不同,被动转移大量可广泛中和艾滋病毒的单抗显示出戏剧性的保护,使其免受一天后给予SIV分离株的致命挑战。然而,在传统的表达系统中生产这些重组蛋白的成本将是过高的,而更便宜的系统是高度优先的。在这项提案中,这些单抗将在烟草植物中生产,它们在体外中和艾滋病毒的能力以及在体内保护猴子的能力将与目前使用的昂贵的CHO来源的单抗进行比较。
英文摘要
DESCRIPTION (provided by applicant): While many HIV vaccine regimens have elicited robust viral-specific T cell responses, they have been unable to prevent infection. To date, passive immunotherapy with a small number of broadly neutralizing monoclonal antibodies (MAbs) given in combination have afforded the best protection against SHIV challenge in monkeys. However, in a global context, the large multiple doses required will create excessive demands on existing expensive microbial fermentation or cell-based production systems. Plant expression will provide an inexpensive, safe, and rapidly scalable alternative. Genetically engineered plants have been successfully used to produce many complex proteins, as diverse as IgG, sIgA, vaccine antigens, enzymes and growth factors. The aim of this Phase I study is to produce highly expressing MAbs in plants using Agrobacterium infiltration/ injection and assess their ability to broadly neutralize HIV-1 isolates in vitro. Several well characterized envelope-specific MAbs will be produced in tobacco; 2G12, 2F5, 4E10, IgG1b12 as well as a MAb against a CD4-inducible gp120 epitope. In order to examine, the effect of N-glycosylation on neutralization by these MAbs, both the ER- retained "high mannose" and the secreted "complex glycan" forms will be produced and compared to CHO-derived proteins. Concomitant with these studies, the slower process of generating stable transgenic tobacco plants will be initiated. This will be aided by coexpression of the DsRed fluorescent marker to identify antibody expressing lines and trace transgenic offspring. In the current environment, the use of a non-food, non-feed crop to produce important therapeutic proteins offers many advantages. In Phase II, those MAbs that are both expressed at high levels and have strong neutralizing activity will be produced by either transgenic plants or by large scale transient expression of tobacco plants and tested for their ability to prevent infection of monkeys challenged with an SHIV isolate. PUBLIC HEALTH RELEVANCE: Unlike HIV vaccines, the passive transfer of large amounts of monoclonal antibodies that broadly neutralize HIV virus has shown dramatic protection against a lethal challenge with a SHIV isolate given one day later. However, the cost of producing these recombinant proteins in traditonal expression systems would be exorbitant and a more inexpensive system is a high priority. In this proposal, these MAbs will be produced in tobacco plants and their ability to neutralize HIV in vitro and to protect monkeys in vivo will be compared to currently used and expensive CHO-derived MAbs.
期刊论文(2)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1371/journal.pone.0152760
发表时间: 2016
期刊: PloS one
影响因子: 3.7
作者: [Rosenberg YJ, Montefiori DC, LaBranche CC, Lewis MG, Sack M, Lees JP, Jiang X]
通讯作者: Jiang X
Zwitterionic oxime (RS194B) to reverse advanced symptoms and lethality of organophosphate pesticide exposure
  • 批准号:
    9621314
  • 项目类别:
  • 资助金额:
    $22.49万
  • 财政年份:
    2018
  • 负责人:
    Yvonne J Rosenberg
  • 依托单位:
Development of a handheld PEST-pen device for the rapid detection of organophosphate insecticides on food and clothing
  • 批准号:
    10079784
  • 项目类别:
  • 资助金额:
    $70.58万
  • 财政年份:
    2018
  • 负责人:
    Yvonne J Rosenberg
  • 依托单位:
Development of a handheld PEST-pen device for the rapid detection of organophosphate insecticides on food and clothing
  • 批准号:
    10259769
  • 项目类别:
  • 资助金额:
    $51.51万
  • 财政年份:
    2018
  • 负责人:
    Yvonne J Rosenberg
  • 依托单位:
Plant-derived HIV neutralizing mAbs for passive immunotherapy in newborn macaques
  • 批准号:
    9312216
  • 项目类别:
  • 资助金额:
    $100.0万
  • 财政年份:
    2016
  • 负责人:
    Yvonne J Rosenberg
  • 依托单位:
海外基金